The Effect of Lavender Aromatherapy on Cognitive Function in Older Adults With Mild Cognitive Impairment
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: aromatherapy.
- Who it may be relevant to
- Registry conditions: MCI. Basic parameters: 60 years — 95 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
1. To analyze the therapeutic effects of lavender aromatherapy on memory function and overall cognitive function in older adults with Mild Cognitive Impairment (MCI); 2. To analyze whether lavender aromatherapy improves executive function, language ability, attention, visuospatial ability, anxiety, depression, quality of life, and sleep in older adults with MCI.
Detailed description
The intervention protocol was established as follows: Based on the elderly participant's usual bedtime, the time of going to bed was recorded. The participant was instructed to assume a comfortable sleeping position, use the graduated dropper provided with the essential oil bottle to measure 0.15 ml (approximately 3 drops; theoretically, 0.05 ml per drop) of diluted lavender essential oil, and drip it vertically onto the upper center of a cotton pad. The cotton pad was then pinned to the collar with a safety pin, and the participant was instructed to inhale the scent evenly for 30 minutes. Afterward, the intervention staff or caregiver will remove the cotton pad. The intervention will be conducted 5 days a week for 12 weeks.
Interventions
- Other aromatherapy
Participants in the intervention group will receive aromatherapy inhalation for 30 minutes per session, five times a week, over a period of 12 week
Primary outcome measures
- Gobal cognitive function [Time frame: Week 12]
- Memory [Time frame: Week 12]
Secondary outcome measures (8)
- Language function [Time frame: Week 12]
- Executive function [Time frame: Week 12]
- Visual space [Time frame: Week 12]
- Attention [Time frame: Week 12]
- Anxiety [Time frame: Week 12]
- Depression [Time frame: Week 12]
- Sleep Quality [Time frame: Week 12]
- Quality of Life assess [Time frame: Week 12]
Eligibility criteria
Inclusion criteria
- The MCI mentioned in this study meets the diagnostic criteria proposed by the \*Chinese Expert Consensus on the Diagnosis and Treatment of Alzheimer's Disease-Derived Mild Cognitive Impairment (2021)\*: cognitive impairment reported by the patient or an informant, or identified by an experienced clinician; objective evidence of impairment in one or more cognitive domains, with episodic memory impairment being the most common; complex instrumental activities of daily living may be mildly impaired, but the ability to perform basic activities of daily living remains independent; the diagnostic criteria for dementia are not met.
- MoCA-Beijing version scores were adjusted for education level: ≤13 for junior high school education or below, ≤19 for high school education, and ≤24 for university education or above; MMSE score >24; ADL score <23.
- Age between 60 and 79 years.
- Normal olfactory function assessed using the "Sniffin' Sticks" test.
- Ability to communicate normally and complete cognitive assessments.
- Residing in a senior care facility with no plans to leave within the next 12 weeks.
Exclusion criteria
- Presence of other conditions known to affect cognitive function, such as psychiatric disorders (e.g., schizophrenia, depression).
- History of asthma or any allergic conditions.
- Use of any prescription medications that may impact cognitive function (including psychotropic drugs and others)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07688382 · Lun Shen [2025] No. 237